Precision medicine and new treatments in malignant lymphomas

This research program aims to develop precision medicine in lymphomas and evaluate uptake and side-effects of new lymphoma treatments.

The first work package (WP1) aims to identify additional diagnostic, prognostic and predictive markers to support treatment choices and improve lymphoma survival.

In multidisciplinary collaboration, we will develop and use next-generation sequencing (NGS) of tumor tissue and plasma (cell-free tumor DNA) in an ongoing prospective study (n=600) and correlate with diagnostic characteristics and outcome during 2025-2028 (applicant is principal investigator).

Cell-free tumor DNA monitoring is a novel powerful tool that could substantially impact lymphoma care in the near future.

The second WP includes a national population-based register study aiming to better understand uptake and side-effects of new treatments in lymphoma and improve patient care.

The recent development of novel targeted and cellular therapies (e.g., CAR-T) has led to dramatically improved survival for selected patients, but post-treatment side-effects are largely undefined.

WP2 is based on the Swedish Lymphoma Register (applicant is register holder), and will include patients diagnosed 2015 and onwards (n=20,000), a population comparison group matched 10:1 to the patients, and linkage to other nationwide health care registers.

The project is unique in an international perspective given the large yet clinically detailed data source, and the population comparison.